GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘Remove the risk and there is nothing left to make’: Crispy Studio Co-Founder reflects on creative sectors
The Culture Minister has recently described his first months overseeing the culture portfolio as “traumatic”.
Tina Lombardi takes charge of MIA’s Traffic Development Department
Her expanded role follows the departure of Alex Cardona.
Natasha Giorgio appointed Chief Commercial Officer at SoftConstruct
She brings extensive experience in commercial strategy, business development and the iGaming industry.
Nicolai Portelli named CEO of Charles de Giorgio Ltd
He brings extensive management experience, having held senior positions across many industries.
